About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Pparg
peroxisome proliferator activated receptor gamma
MGI:97747
255 phenotypes from 25 alleles in 30 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Ppargm1Btlr/Ppargm1Btlr
C57BL/6J-Ppargm1Btlr 		decreased body weight J:265098
Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Ppargtm1.1Auw 		abnormal bone structure J:144344
abnormal cell differentiation J:144344
abnormal circadian temperature homeostasis J:144344
decreased body mass index J:144344
decreased body weight J:144344
decreased circulating cholesterol level J:144344
decreased circulating triglyceride level J:144344
decreased total fat pad weight J:144344
extended life span J:144344
normal homeostasis/metabolism phenotype J:144344
hyperactivity J:144344
improved glucose tolerance J:144344
increased adipocyte glucose uptake J:144344
increased fluid intake J:144344
increased insulin sensitivity J:144344
Ppargtm1.1Auw/Ppargtm1.1Auw
either: 129 or C57BL/6J or (involves: 129 * C57BL/6J) 		normal adipose tissue phenotype J:86705
Ppargtm1.1Gonz/Ppargtm1.1Gonz
involves: 129X1/SvJ * FVB 		cardiac hypertrophy J:112034
decreased heart rate J:112034
increased myocardial fiber size J:112034
Ppargtm1.1Gonz/Ppargtm1.1Gonz
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 		abnormal kidney morphology J:168799
abnormal macrophage activation involved in immune response J:168799
abnormal nephron morphology J:168799
abnormal peritoneal macrophage morphology J:168799
abnormal podocyte foot process morphology J:168799
abnormal renal glomerulus morphology J:168799
albuminuria J:168799
enlarged kidney J:168799
expanded mesangial matrix J:168799
fused podocyte foot processes J:168799
glomerulonephritis J:168799
impaired macrophage phagocytosis J:168799
increased anti-double stranded DNA antibody level J:168799
increased anti-nuclear antigen antibody level J:168799
increased anti-single stranded DNA antibody level J:168799
increased autoantibody level J:168799
increased circulating creatine level J:168799
increased IgG level J:168799
increased IgM level J:168799
increased kidney weight J:168799
increased mesangial cell number J:168799
increased renal glomerulus apoptosis J:168799
increased renal glomerulus basement membrane thickness J:168799
increased urine protein level J:168799
renal glomerulus hypertrophy J:168799
Ppargtm1.1Gonz/Ppargtm1.1Gonz
Tg(Aqp2-cre)1Dek/0
involves: 129X1/SvJ * C57BL/6 * SJL 		abnormal blood volume J:99873
abnormal body weight J:99873
abnormal circulating aldosterone level J:99873
abnormal hematocrit J:99873
abnormal physiological response to xenobiotic J:99873
abnormal renal sodium ion transport J:99873
abnormal urine sodium level J:99873
Ppargtm1.1Gonz/Ppargtm1.1Gonz
Tg(Ins2-cre)25Mgn/0
involves: 129 * C57 * FVB 		pancreatic islet hyperplasia J:89959
Ppargtm1.1Gonz/Ppargtm1.1Gonz
Tg(Mx1-cre)1Cgn/?
involves: 129X1/SvJ * C57BL/6 * CBA * FVB/N 		abnormal macrophage physiology J:75777
Ppargtm1.1Mgn/Ppargtm1.1Mgn
involves: 129S6/SvEvTac * C57BL/6J 		no abnormal phenotype detected J:75120
Ppargtm1.1Mtz/Ppargtm1.1Mtz
involves: C57BL/6 		abnormal placenta development J:89238
embryonic lethality during organogenesis, complete penetrance J:89238
Ppargtm1.2Auw/Ppargtm1.2Auw
B6.Cg-Ppargtm1.2Auw 		premature death J:161746
Ppargtm1.2Mgn/Ppargtm1.2Mgn
involves: 129S6/SvEvTac * C57BL/6J 		prenatal lethality, complete penetrance J:75120
Ppargtm1.2Mtz/Ppargtm1.2Mtz
Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6 		abnormal adipose tissue physiology J:89238
abnormal brown fat cell morphology J:89238
abnormal white fat cell morphology J:89238
decreased brown adipose tissue amount J:89238
decreased epididymal fat pad weight J:89238
decreased percent body fat/body weight J:89238
increased brown fat cell lipid droplet size J:89238
Ppargtm1.2Mtz/Ppargtm1.2Mtz
Tg(Krt10-cre/ERT2)1Pcn/0
involves: C57BL/6 * SJL 		abnormal keratinocyte morphology J:109090
abnormal skin morphology J:109090
Ppargtm1.2Mtz/Ppargtm1.2Mtz
Tg(KRT14-cre)1Ipc/0
involves: C57BL/6 * SJL 		no abnormal phenotype detected J:109090
Ppargtm1Auw/Ppargtm1Auw
either: 129 or C57BL/6J or (involves: 129 * C57BL/6J) 		abnormal brown adipose tissue morphology J:86705
abnormal circulating alanine transaminase level J:86705
abnormal glucose homeostasis J:86705
decreased body temperature J:86705
decreased body weight J:86705
decreased brown adipose tissue mass J:86705
decreased white adipose tissue mass J:86705
enlarged liver J:86705
hyperlipidemia J:86705
impaired glucose tolerance J:86705
increased circulating aspartate transaminase level J:86705
increased circulating free fatty acids level J:86705
increased circulating triglyceride level J:86705
increased liver triglyceride level J:86705
insulin resistance J:86705
lipodystrophy J:86705
macrovesicular hepatic steatosis J:86705
postnatal growth retardation J:86705
postnatal lethality, incomplete penetrance J:86705
Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6 		abnormal adipose tissue distribution J:116568
abnormal fat cell differentiation J:116568
abnormal lipid homeostasis J:116568
abnormal triglyceride level J:116568
decreased circulating adiponectin level J:116568
normal growth/size/body region phenotype J:116568
hepatic steatosis J:116568
normal homeostasis/metabolism phenotype J:116568
increased circulating triglyceride level J:116568
increased liver weight J:116568
Ppargtm1Avp/Ppargtm1Avp
involves: 129S2/SvPas * C57BL/6 		preweaning lethality, complete penetrance J:116568
Ppargtm1b(KOMP)Wtsi/Pparg+
C57BL/6N-Ppargtm1b(KOMP)Wtsi/H 		abnormal gait J:211773
decreased lean body mass J:211773
increased fasting circulating glucose level J:211773
increased total body fat amount J:211773
Ppargtm1b(KOMP)Wtsi/Ppargtm1b(KOMP)Wtsi
C57BL/6N-Ppargtm1b(KOMP)Wtsi/H 		embryonic lethality prior to tooth bud stage J:211773
preweaning lethality, complete penetrance J:211773
Ppargtm1Gonz/Ppargtm1Gonz
Tg(MMTV-cre)1Mam/?
involves: 129X1/SvJ * FVB 		abnormal mammary gland growth during pregnancy J:76553
decreased litter size J:76553
female infertility J:76553
reduced female fertility J:76553
Ppargtm1Gonz/Ppargtm1Gonz
Tg(MMTV-cre)4Mam/?
involves: 129X1/SvJ * FVB 		normal reproductive system phenotype J:76553
Ppargtm1Gonz/Ppargtm1Gonz
Tg(Wap-cre)11738Mam/?
involves: 129X1/SvJ * C57BL/6 * SJL 		normal reproductive system phenotype J:76553
Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6 		abnormal glucose homeostasis J:135904
decreased circulating free fatty acids level J:135904
decreased circulating leptin level J:135904
decreased circulating triglyceride level J:135904
decreased fat cell size J:135904
improved glucose tolerance J:135904
increased circulating adiponectin level J:135904
increased insulin sensitivity J:135904
Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ 		abnormal brown fat cell morphology J:98786
abnormal epididymal fat pad morphology J:98786
decreased body fat mass J:98786
decreased body weight J:98786
decreased circulating adiponectin level J:98786
decreased skeletal muscle cell glucose uptake J:98786
decreased white fat cell size J:98786
hypertension J:98786
increased circulating free fatty acids level J:98786
increased circulating insulin level J:98786
increased liver triglyceride level J:98786
insulin resistance J:98786
lipodystrophy J:98786
macrovesicular hepatic steatosis J:98786
microvesicular hepatic steatosis J:98786
Ppargtm1Lja/Ppargtm1Lja
involves: 129S1/Sv * 129X1/SvJ 		decreased embryo size J:98786
embryonic lethality, complete penetrance J:98786
Ppargtm1Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6 		abnormal adipose tissue distribution J:91362
abnormal endocrine pancreas morphology J:91362
abnormal fat cell morphology J:91362
abnormal gonadal fat pad morphology J:91362
abnormal inguinal fat pad morphology J:91362
hypertension J:91362
improved glucose tolerance J:91362
Ppargtm1Mae/Ppargtm1Mae
involves: 129S6/SvEvTac * C57BL/6 		prenatal lethality, complete penetrance J:91362
Ppargtm1Rev/Pparg+
involves: 129S4/SvJae * C57BL/6J 		abnormal glucose homeostasis J:60354
increased insulin sensitivity J:60354
Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae 		abnormal chorionic plate morphology J:58223
abnormal fetal cardiomyocyte mitochondrial morphology J:58223
abnormal fetal cardiomyocyte morphology J:58223
abnormal myocardial trabeculae morphology J:58223
abnormal placenta hemotrichorial membrane morphology J:58223
abnormal placenta labyrinth morphology J:58223
abnormal placenta morphology J:58223
abnormal placental labyrinth vasculature morphology J:58223
abnormal trophoblast giant cell morphology J:58223
abnormal trophoblast layer morphology J:58223
embryonic lethality during organogenesis, complete penetrance J:58223
thin interventricular septum J:58223
thin myocardium J:58223
thin ventricle myocardium compact layer J:58223
thin ventricular wall J:58223
Ppargtm1Rev/Ppargtm2Mae
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6J 		increased systemic arterial blood pressure J:154767
Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA 		abnormal bone marrow development J:89250
abnormal bone marrow morphology J:89250
abnormal bone ossification J:89250
abnormal cell differentiation J:58222
abnormal fat cell morphology J:58222, J:89250
abnormal osteoblast differentiation J:89250
abnormal response to injury J:103209
abnormal retina vasculature morphology J:116269
decreased brown adipose tissue amount J:58222
decreased circulating insulin level J:58222
decreased food intake J:58222
decreased susceptibility to diet-induced hepatic steatosis J:58222
decreased susceptibility to diet-induced obesity J:58222
decreased total body fat amount J:58222
increased body temperature J:58222
increased circulating leptin level J:58222
increased incidence of tumors by chemical induction J:98823
increased insulin sensitivity J:58222
increased osteoblast cell number J:89250
increased susceptibility to xenobiotic induced morbidity/mortality J:98823
increased trabecular bone mass J:89250
leukostasis J:116269
normal skeleton phenotype J:89250
Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA * ICR 		abnormal B cell physiology J:58222
abnormal humoral immune response J:58222
abnormal response to injury J:68579
normal immune system phenotype J:58222
increased B cell proliferation J:58222
increased IgG level J:58222
increased IgM level J:58222
increased interferon-gamma secretion J:58222
increased interleukin-2 secretion J:58222
increased susceptibility to induced arthritis J:58222
Ppargtm1Tka/Ppargtm1Tka
involves: C57BL/6 * CBA 		abnormal cell differentiation J:58222, J:89250
abnormal heart development J:58222
abnormal placenta labyrinth morphology J:58222
abnormal placental labyrinth vasculature morphology J:58222
embryonic growth retardation J:58222
embryonic lethality during organogenesis, complete penetrance J:58222
placental labyrinth hypoplasia J:58222
thin myocardium J:58222
Ppargtm1Uls/Pparg+
involves: 129S2/SvPas * C57BL/6 		decreased total body fat amount J:92826
postnatal growth retardation J:92826
Ppargtm1Uls/Ppargtm1Uls
involves: 129S2/SvPas * C57BL/6 		prenatal lethality, complete penetrance J:92826
Ppargtm1Wwah/Pparg+
Not Specified 		normal immune system phenotype J:71272
Ppargtm1Wwah/Ppargtm1Wwah
Not Specified 		prenatal lethality J:71272
Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6 		abnormal brown adipose tissue morphology J:91479
abnormal white adipose tissue morphology J:91479
abnormal white adipose tissue physiology J:91479
decreased body weight J:91479
decreased brown fat cell lipid droplet size J:91479
decreased brown fat lipid droplet number J:91479
decreased circulating adiponectin level J:91479
decreased circulating leptin level J:91479
decreased gonadal fat pad weight J:91479
decreased inguinal fat pad weight J:91479
decreased retroperitoneal fat pad weight J:91479
decreased white adipose tissue amount J:91479
decreased white fat cell number J:91479
decreased white fat cell size J:91479
insulin resistance J:91479
normal liver/biliary system phenotype J:91479
Ppargtm2(tTA)Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6 		abnormal brown adipose tissue morphology J:125992
abnormal hepatocyte morphology J:125992
abnormal white adipose tissue morphology J:125992
abnormal white fat cell morphology J:125992
abnormal white fat cell size J:125992
absent subcutaneous adipose tissue J:125992
normal adipose tissue phenotype J:125992
decreased gonadal fat pad weight J:125992
enlarged liver J:125992
normal homeostasis/metabolism phenotype J:125992
hyperglycemia J:125992
impaired glucose tolerance J:125992
increased brown fat cell size J:125992
increased circulating cholesterol level J:125992
increased circulating free fatty acids level J:125992
increased circulating insulin level J:125992
increased circulating triglyceride level J:125992
increased interscapular fat pad weight J:125992
insulin resistance J:125992
pancreas hyperplasia J:125992
pancreatic islet hyperplasia J:125992
reduced fertility J:125992
Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6 		abnormal pancreatic islet morphology J:121534
decreased circulating adiponectin level J:121534
Ppargtm2Avp/Ppargtm2Avp
Not Specified 		abnormal adipose tissue distribution J:121693
abnormal glucose homeostasis J:121693
abnormal white adipose tissue physiology J:121693
decreased circulating adiponectin level J:121693
decreased total body fat amount J:121693
impaired glucose tolerance J:121693
increased circulating glucose level J:121693
increased circulating leptin level J:121693
increased fat cell size J:121693
normal reproductive system phenotype J:121693
Ppargtm2Rev/Ppargtm2Rev
Tg(Camk2a-cre)62Jzt/?
B6.Cg-Ppargtm2Rev Tg(Camk2a-cre)62Jzt 		abnormal neuron physiology J:148757
normal behavior/neurological phenotype J:148757
brain ischemia J:148757
normal growth/size/body region phenotype J:148757
normal homeostasis/metabolism phenotype J:148757
normal nervous system phenotype J:148757
Ppargtm2Rev/Ppargtm2Rev
Tg(Cd4-cre)1Cwi/?
involves: 129S4/SvJae * C57BL/6 * DBA/2 		abnormal T-helper 17 cell differentiation J:153358
increased susceptibility to experimental autoimmune encephalomyelitis J:153358
Ppargtm2Rev/Ppargtm2Rev
Tg(Fabp4-cre)1Rev/0
involves: 129S4/SvJae * C57BL/6 		abnormal brown adipose tissue morphology J:88210
abnormal brown fat cell size J:88210
abnormal white adipose tissue amount J:88210
decreased brown adipose tissue amount J:88210
decreased brown fat cell number J:88210
decreased interscapular fat pad weight J:88210
enlarged liver J:88210
hepatic steatosis J:88210
increased brown fat cell size J:88210
increased circulating insulin level J:88210
increased white fat cell size J:88210
insulin resistance J:88210
slow postnatal weight gain J:88210
Ppargtm2Rev/Ppargtm2Rev
Tg(Krt1-15-cre/PGR*)22Cot/?
involves: 129S4/SvJae * C57BL/6 * SJL 		abnormal coat appearance J:150977
abnormal hair follicle morphology J:150977
abnormal hair follicle ostium morphology J:150977
abnormal skin adnexa morphology J:150977
abnormal skin appearance J:150977
abnormal skin morphology J:150977
abnormal skin sebaceous gland morphology J:150977
excessive scratching J:150977
flaky skin J:150977
hyperkeratosis J:150977
matted coat J:150977
progressive hair loss J:150977
reddish skin J:150977
sebaceous gland atrophy J:150977
skin fibrosis J:150977
skin inflammation J:150977
Ppargtm2Rev/Ppargtm2Rev
Tg(Lhb-cre)1Sac/?
involves: 129S4/SvJae * C57BL/6 * SJL 		abnormal diestrus J:170272
decreased circulating follicle stimulating hormone level J:170272
decreased litter size J:170272
increased luteinizing hormone level J:170272
normal reproductive system phenotype J:170272
Ppargtm2Rev/Ppargtm2Rev
Tg(Tagln-cre)1Her/?
involves: 129S4/SvJae * C57BL/6 * SJL 		abnormal pulmonary artery morphology J:136168
heart right ventricle hypertrophy J:136168
increased right ventricle systolic pressure J:136168
Ppargtm2Rev/Ppargtm2Rev
Tg(Tek-cre)1Ywa/?
involves: 129S4/SvJae * C57BL/6 * SJL 		abnormal bone marrow cavity morphology J:130475
abnormal bone marrow cell morphology/development J:130475
abnormal bone structure J:130475
abnormal bone trabecula morphology J:130475, J:160910
abnormal hair cycle J:123403
abnormal hair cycle anagen phase J:123403
abnormal hair follicle morphology J:123403
abnormal hair shedding J:123403
abnormal mammary gland alveolus morphology J:123403
abnormal osteoclast differentiation J:160910
abnormal osteoclast morphology J:130475
abnormal pulmonary artery morphology J:155909
abnormal skin adnexa morphology J:123403
abnormal spleen morphology J:130475
abnormal splenocyte morphology J:130475
abnormal trabecular bone morphology J:130475
decreased bone marrow cell number J:130475
decreased osteoclast cell number J:130475
enlarged spleen J:130475
extramedullary hematopoiesis J:130475
heart right ventricle hypertrophy J:155909
normal hematopoietic system phenotype J:130475
increased bone mineral density J:130475
increased bone trabecula number J:130475
increased bone volume J:130475
increased right ventricle systolic pressure J:155909
increased splenocyte number J:130475
increased trabecular bone thickness J:130475
increased trabecular bone volume J:130475
increased triglyceride level J:155909
pale liver J:123403
postnatal growth retardation J:123403
premature hair loss J:123403
skin inflammation J:123403
Ppargtm2Rev/Ppargtm2Rev
Tg(Tek-cre)12Flv/?
B6.Cg-Ppargtm2Rev Tg(Tek-cre)12Flv 		abnormal vascular endothelial cell physiology J:154216
abnormal vasodilation J:154216
decreased body weight J:154216
decreased hematocrit J:154216
enlarged spleen J:154216
impaired muscle relaxation J:154216
increased mean systemic arterial blood pressure J:154216
Ppargtm2Rev/Ppargtm2Rev
Tg(Ucp1-cre)1Evdr/0
involves: 129S4/SvJae * FVB 		abnormal amino acid metabolism J:278806
abnormal interscapular fat pad morphology J:278806
Ppargtm3(tTA)Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6 		abnormal brown adipose tissue morphology J:125992
abnormal brown fat cell morphology J:125992
decreased gonadal fat pad weight J:125992
decreased subcutaneous adipose tissue amount J:125992
enlarged liver J:125992
increased brown fat cell size J:125992
increased circulating insulin level J:125992
increased circulating triglyceride level J:125992
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory